These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

142 related items for PubMed ID: 19850503

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.
    Al-Sha'er MA, Khanfar MA, Taha MO.
    J Mol Model; 2014 Jan; 20(1):2080. PubMed ID: 24469103
    [Abstract] [Full Text] [Related]

  • 27. Application of validated QSAR models of D1 dopaminergic antagonists for database mining.
    Oloff S, Mailman RB, Tropsha A.
    J Med Chem; 2005 Nov 17; 48(23):7322-32. PubMed ID: 16279792
    [Abstract] [Full Text] [Related]

  • 28. Elaborate ligand-based modeling coupled with multiple linear regression and k nearest neighbor QSAR analyses unveiled new nanomolar mTOR inhibitors.
    Khanfar MA, Taha MO.
    J Chem Inf Model; 2013 Oct 28; 53(10):2587-612. PubMed ID: 24050502
    [Abstract] [Full Text] [Related]

  • 29. Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors.
    Abuhamdah S, Habash M, Taha MO.
    J Comput Aided Mol Des; 2013 Dec 28; 27(12):1075-92. PubMed ID: 24338032
    [Abstract] [Full Text] [Related]

  • 30. Use of binding energy in comparative molecular field analysis of isoform selective estrogen receptor ligands.
    Wolohan P, Reichert DE.
    J Mol Graph Model; 2004 Sep 28; 23(1):23-38. PubMed ID: 15331051
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
    Yu H, Wang Z, Zhang L, Zhang J, Huang Q.
    Bioorg Med Chem Lett; 2007 Apr 15; 17(8):2126-33. PubMed ID: 17306530
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. QSAR study of selective ligands for the thyroid hormone receptor beta.
    Liu H, Gramatica P.
    Bioorg Med Chem; 2007 Aug 01; 15(15):5251-61. PubMed ID: 17524652
    [Abstract] [Full Text] [Related]

  • 35. Structure-based design of estrogen receptor-beta selective ligands.
    Manas ES, Unwalla RJ, Xu ZB, Malamas MS, Miller CP, Harris HA, Hsiao C, Akopian T, Hum WT, Malakian K, Wolfrom S, Bapat A, Bhat RA, Stahl ML, Somers WS, Alvarez JC.
    J Am Chem Soc; 2004 Nov 24; 126(46):15106-19. PubMed ID: 15548008
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Pyrazolo[1,5-a]pyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity.
    Compton DR, Sheng S, Carlson KE, Rebacz NA, Lee IY, Katzenellenbogen BS, Katzenellenbogen JA.
    J Med Chem; 2004 Nov 18; 47(24):5872-93. PubMed ID: 15537344
    [Abstract] [Full Text] [Related]

  • 39. Application of predictive QSAR models to database mining: identification and experimental validation of novel anticonvulsant compounds.
    Shen M, Béguin C, Golbraikh A, Stables JP, Kohn H, Tropsha A.
    J Med Chem; 2004 Apr 22; 47(9):2356-64. PubMed ID: 15084134
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.